Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Trinity Biotech ( (TRIB) ) has issued an announcement.
Trinity Biotech announced on January 28, 2025, significant advancements in its continuous glucose monitoring (CGM) technology following a successful pre-pivotal trial. The trial highlighted exceptional performance improvements, including superior signal quality and enhanced sensor reliability and accuracy. This breakthrough is expected to substantially lower costs and expand access to CGM technology, positioning Trinity as a competitive player in the projected $20 billion CGM market by 2029. The company plans to further clinical trials and pursue regulatory approvals in the EU in 2025 and the US in 2026.
More about Trinity Biotech
Trinity Biotech is a commercial-stage biotechnology company specializing in diabetes management solutions and human diagnostics, including wearable biosensors. The company develops and markets diagnostic systems for point-of-care and clinical laboratory segments and has recently entered the wearable biosensor market through the acquisition of Waveform Technologies Inc. Trinity Biotech operates globally, selling products directly in the United States and through international distributors in over 75 countries.
YTD Price Performance: -19.92%
Average Trading Volume: 169,658
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $8.85M
See more data about TRIB stock on TipRanks’ Stock Analysis page.
